GF CSI Innovative Drugs Industry ETF(515120) Falls 1.59%, Sees Net Inflow of 212 Million Yuan Over the Past 5 Trading Days

NewTimeSpace News, as of 13:56 on May 13, 2026, GF Innovative Drug ETF (515120) fell 1.59%, with its latest quoted price at 0.62 yuan. Looking at a longer timeframe, as of May 12, 2026, GF Innovative Drug ETF gained 0.64% over the past week. (The stocks listed above are merely index constituents and do not constitute any specific recommendation.)

In terms of liquidity, GF Innovative Drug ETF recorded an intraday turnover rate of 3.98%, with a trading volume of 381 million yuan. Over a longer horizon, as of May 12, the ETF's average daily turnover over the past week stood at 507 million yuan, ranking in the top 2 among comparable funds.

Regarding scale, GF Innovative Drug ETF's AUM increased by 158 million yuan over the past week, achieving significant growth, with the new scale increment ranking 2/7 among comparable funds. (Data source: Wind)

In terms of share size, GF Innovative Drug ETF's share count increased by 165 million units over the past week, achieving significant growth, with the new share increment ranking 2/7 among comparable funds. (Data source: Wind)

In terms of capital inflows, the latest net outflow for GF Innovative Drug ETF was 57.9631 million yuan. Looking at a longer timeframe, over the past five trading days, there were four days of net inflows, totaling 212 million yuan, with an average daily net inflow of 42.4961 million yuan. (Data source: Wind)

Data shows that leveraged funds continue to position themselves. The net margin purchase amount for GF Innovative Drug ETF on the previous trading day reached 11.9307 million yuan, and the latest margin balance stood at 342 million yuan. (Data source: Wind)

As of May 12, GF Innovative Drug ETF's net value increased by 17.99% over the past two years. In terms of return capability, as of May 12, 2026, since its inception, the ETF achieved a highest single-month return of 23.00%, a longest consecutive gaining streak of five months with a cumulative gain of 32.68%, and an average return of 5.50% during up months. As of May 12, 2026, the ETF's annualized excess return over its benchmark over the past two years was 0.89%.

In terms of drawdown, as of May 12, 2026, GF Innovative Drug ETF's relative drawdown versus its benchmark since the beginning of the year was 0.14%, indicating relatively low drawdown risk among comparable funds.

In terms of fees, GF Innovative Drug ETF has a management fee rate of 0.50% and a custody fee rate of 0.10%.

In terms of tracking accuracy, as of May 12, 2026, GF Innovative Drug ETF's tracking error since the beginning of the year was 0.010%, the highest tracking precision among comparable funds.

From a valuation perspective, the latest price-to-earnings ratio (PE-TTM) of the CSI Innovative Drug Industry Index, which GF Innovative Drug ETF tracks, is only 48.94 times, placing it at the 17.62nd percentile over the past year—meaning the valuation is lower than that of over 82.38% of the time in the past year, indicating a historically low level.

GF Innovative Drug ETF closely tracks the CSI Innovative Drug Industry Index. The CSI Innovative Drug Industry Index selects no more than 50 of the most representative listed company securities whose main business involves innovative drug research and development as index constituents, in order to reflect the overall performance of listed company securities in the innovative drug industry.

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.